Articles

How low should sample volume go?

By addressing the challenges and harnessing the opportunities of miniaturized assays, researchers have unlocked powerful new applications in candidate screening.
Written bySarah Anderson, PhD
| 6 min read
A pipette tip dispenses liquid into a well plate.

Researchers use liquid handling technology to precisely dispense small volumes for miniaturized drug screens.

credit: istock/nicolas_

Sitting in chemical libraries in labs across the world are compounds waiting to become drugs. When researchers screen hundreds of thousands of these compounds against a specific drug target, a lucky handful might show promise. Some may even overcome every hurdle along the drug discovery pipeline to become an approved drug. Even then, their journey isn’t necessarily complete. They may be combined with other approved or investigational drugs to enhance their efficacy, generating another enormous collection of samples that will get screened all over again.

The ability to search a seemingly never-ending sample space in drug screening campaigns depends on miniaturization: decreasing the sample volume used to test a drug’s activity and adapting compound synthesis and sample preparation protocols for a smaller scale. By reducing reagent consumption and cost, miniaturization has made it possible to analyze massive numbers of samples in early-phase drug discovery. The lower material needs of miniaturized systems also enable researchers to screen drugs in cells derived from patients, facilitating translation to the clinic.

As sample volumes approach the nanoliter range in highly miniaturized systems, it’s only natural to wonder if the reliability of the results also downsizes. While shrinking down samples poses both logistical and scientific challenges, researchers have found solutions everywhere from advanced technology to simple laboratory hacks to souped-up statistical analysis. By developing robust assays and respecting their limitations, scientists can ensure that small samples have an enormous impact.

Well, well, well

The key to a robust assay at any scale is rigorous development, optimization, and validation. Before screening drugs in 384- or 1,536-well plates, researchers evaluate an assay’s performance by measuring parameters like signal variation between samples, signal-to-background ratio, and Z-factor (a numerical value that represents its ability to distinguish between positive and negative controls). “We’ll start to miniaturize, and we’ll see how those metrics hold up,” said Douglas Auld, a high-throughput biologist at the Novartis Institutes for BioMedical Research (NIBR).

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

  • Sarah Anderson, PhD

    Sarah Anderson joined Drug Discovery News as an assistant editor in 2022. She earned her PhD in chemistry and master’s degree in science journalism from Northwestern University. She served as managing editor of the Illinois Science Council’s “Science Unsealed” blog and has written for Discover Magazine, Astronomy Magazine, Chicago Health Magazine, and others. She enjoys reading at the beach, listening to Taylor Swift, and cuddling her cat, Augustus.

    View Full Profile

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D molecular visualization of a protein structure, rendered in a ribbon diagram style.
A comparative structural analysis of MC4R complexes reveals how agonist binding influences receptor conformation, ligand interactions, and complex stability.
Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.